No interaction studies have been performed. There is no known risk of pharmacokinetic interaction with etelcalcetide.
In vitro, etelcalcetide did not inhibit or induce CYP450 enzymes and was itself not a substrate for metabolism by CYP450 enzymes. In vitro, etelcalcetide was not a substrate of efflux and uptake transporter proteins; and etelcalcetide was not an inhibitor of common transporter proteins.
Concurrent administration of other medicinal products known to reduce serum calcium and Parsabiv may result in an increased risk of hypocalcaemia (see Precautions). Patients receiving Parsabiv should not be given cinacalcet (see Precautions).